The lack of stable MB fusion-dependent BCP-ALL cell lines has limited the study of leukemogenesis of MB fusion and development of novel therapies for MEF2D fusion (+) ALL. This evidence concerns the gene MEF2D and acute lymphoblastic leukemia.